Wells Fargo
BBOT

Wells Fargo’s BridgeBio Oncology BBOT Stock Holding History

Wells Fargo’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.69K Hold
300
– – ﹤0.01% 6207
2025
Q4 		$3.76K Buy
+300
New +$3.63K ﹤0.01% 6154

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo's BBOT Position: Q1 2026 in Review

Wells Fargo held its BridgeBio Oncology (BBOT) position steady in Q1 2026 at 300 shares worth $2.69K. The position accounts for ﹤0.01% of the portfolio, ranked #6207.

Wells Fargo first reported a position in BBOT in Q4 2025 and has held it in 2 quarters since. The position peaked at $3.76K in Q4 2025. 67 funds tracked by Wall St. Rank hold BBOT as of Q1 2026.

  • Wells Fargo held 300 shares of BridgeBio Oncology worth $2.69K as of Q1 2026.
  • Wells Fargo left its BridgeBio Oncology share count unchanged in Q1 2026.
  • BridgeBio Oncology made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #6207 holding.
  • Wells Fargo first reported a position in BridgeBio Oncology in Q4 2025 and has held it in 2 quarters since.
  • Wells Fargo's BridgeBio Oncology position peaked at $3.76K in Q4 2025.
  • 67 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.